Last reviewed · How we verify
NCT07407634
A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.
EARLY_PHASE1 trial testing Test drug XTYW007 capsules and placebo,Single dose group in Non-Alcoholic Fatty Liver Disease in 94 participants. Not yet recruiting.
26 February 2027
Quick facts
| Lead sponsor | Xi'an Xintong Pharmaceutical Research Co.,Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 94 |
| Start date | 25 March 2026 |
| Primary completion | 26 February 2027 |
| Estimated completion | 27 May 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Test drug XTYW007 capsules and placebo,Single dose group — full drug profile →
- Test drug XTYW007 capsules and placebo,Food Impact Group — full drug profile →
- Test drug XTYW007 capsules and placebo,Multiple dosing group — full drug profile →
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07407634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other Xi'an Xintong Pharmaceutical Research Co.,Ltd. trials
Trials by the same sponsor.
- NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
- NCT07203118 — A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B · Phase 2, PHASE3 · active not recruiting
- NCT06280534 — Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects · Phase 1 · unknown
- NCT06122454 — A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB · Phase 1, PHASE2 · unknown
- NCT06141109 — Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07407634 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07407634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing